Recombinant human FKBP12 with N-terminal His-tag, expressed in E. coli and purified through a Nichel-affinity chromatography followed by gel filtration.
Recombinant Human FKBP12
FKBP12 is notable in humans for binding the immunosuppressant molecule tacrolimus (originally designated FK506), which is used in treating patients after organ transplant and patients suffering from autoimmune disorders. Tacrolimus has been found to reduce episodes of organ rejection over a related treatment, the drug ciclosporin, which binds cyclophilin. Both the FKBP-tacrolimus complex and the cyclosporin-cyclophilin complex inhibit a phosphatase called calcineurin, thus blocking signal transduction in the T-lymphocyte transduction pathway. This therapeutic role is not related to prolyl isomerase activity.
|Application||Clinical diagnostics| Life Sciences|
|Product type||Reagents for research|
|Reagent type||Recombinant protein|
|Accession number||UniProtKB/Swiss-Prot: P62942.2|
|Form||Liquid, 50mM Hepes pH 8.0, 150mM NaCl, 0,5mM EDTA, 1mM sodium azide|
|Shipping/storage conditions||Shipped at -20°C. The protein is stable for 12 months if stored at -80°C. Avoid repeated freeze/thaw cycles.|
|Usage||For Laboratory Research Use Only|